ArticleMolecular medicine reports2022
3,4‑Dihydroxyacetophenone attenuates oxidative stress‑induced damage to HUVECs via regulation of the Nrf2/HO‑1 pathway.
Article in Molecular medicine reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Characterization of acetovanillone degradation in wild-type and engineeredApplied and environmental microbiology · 2026Article
- Cytotoxicity and Cellular Mechanisms of Novel Polymeric 2,4D Nanopesticide on Human Lung Epithelial A549 Cells.ACS omega · 2026Article
- Synthesis and Health Effects of Phenolic Compounds: A Focus on Tyrosol, Hydroxytyrosol, and 3,4-Dihydroxyacetophenone.Antioxidants (Basel, Switzerland) · 2025Review
- Integration of network-based approaches for assessing variations in metabolic profiles of alkalized and non-alkalized commercial cocoa powders.Food chemistry: X · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been reported that oxidative stress plays a prominent role in diabetic macrovascular diseases. 3,4‑Dihydroxyacetophenone (3,4‑DHAP) has been found to have a variety of biological activities. However, few studies have assessed the antioxidant capacity of 3,4‑DHAP and the underlying mechanisms. Thus, the aim of the present study was to explore the effects of 3,4‑DHAP on oxidative stress in human umbilical vein endothelial cells (HUVECs). HUVECs were pre‑treated with 3,4‑DHAP and then exposed to high glucose conditions. Cell viability and cytotoxicity were measured using an MTT assay. Reactive oxygen species (ROS) levels were measured using an inverted fluorescence microscope and a fluorescent enzyme labeling instrument. Protein expression levels of nuclear factor E2‑related factor 2 (Nrf2), heme oxygenase‑1 (HO‑1), microtubule‑associated protein 1A/1B‑light chain 3 (LC3) and poly ADP‑ribose polymerase‑1 (PARP‑1) were measured using western blotting, and mRNA expression of Nrf2 and HO‑1 were measured through reverse transcription‑quantitative PCR (RT‑qPCR). Nrf2 nuclear translocation was evaluated using immunofluorescence analysis and autophagosomes were observed using transmission electron microscope (TEM). The results of the present study demonstrated that compared with the control group, cell viability of the high glucose group was reduced and cell cytotoxicity of the high glucose group was increased. ROS production in the high glucose group was clearly enhanced. In addition, high glucose upregulated Nrf2 and HO‑1 protein and mRNA expression levels. Nuclear translocation of Nrf2 in the high glucose group was also increased. The formation of autophagosomes in the high glucose group was also higher than that in the control group. Furthermore, LC3‑II/LC3‑I and PARP‑1 protein expression levels were increased after treatment with high glucose. However, compared to the high glucose group, 3,4‑DHAP (10 µmol/l) significantly enhanced cell viability. 3,4‑DHAP markedly decreased the production of ROS, increased Nrf2 and HO‑1 protein and mRNA expression levels, and promoted nuclear translocation of Nrf2 in HUVECs. In addition, 3,4‑DHAP promoted the formation of autophagosomes, and notably increased the protein expression levels of LC3‑II/LC3‑I and PARP‑1. Moreover, it was determined that compared to the 3,4‑DHAP group, treatment with 3,4‑DHAP and ML385 enhanced cell viability, and decreased ROS production, Nrf2 and HO‑1 protein and mRNA expression levels, nuclear translocation of Nrf2, and LC3‑II/LC3‑I and PARP‑1 protein expression levels. Collectively, the results of the present study showed that 3,4‑DHAP protected HUVECs against oxidative stress via regulation of the Nrf2/HO‑1 pathway, by increasing autophagy and promoting DNA damage repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.